Drugs / aPHAD-SE
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06546709 Background | Jan 2025 → May 2026 overdue | Lassa fever | Wilbur Chen, MD, MS | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aPHAD-SE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06546709 ↗ |
| Action | Activate | “TLR-4)-activating oil-in-water emulsion adjuvant” NCT06546709 ↗ |
| Modality | Other / unclassified | “3D-(6- acyl) Phosphorylated Hexaacyl Disaccharides (PHAD)-Stable squalene oil-in-water nanoemulsion (aPHAD-SE) adjuvant administered by IM injection” NCT06546709 ↗ |
| Route | Intramuscular | “Rabies-Vectored Monovalent Lassa Fever Vaccine (LASSARAB) with 3D-(6- acyl) Phosphorylated Hexaacyl Disaccharides (PHAD)-Stable squalene oil-in-water nanoemulsion (aPHAD-SE)...” NCT06546709 ↗ |
| Target | TLR4 | “toll-like receptor (TLR-4)-activating oil-in-water emulsion adjuvant” NCT06546709 ↗ |